Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $34.94M
• Dividend Yield: 9.78%
• Average Volume (3M): 19.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.02
• Revenue Growth: -0.29%
• EPS Growth: 94.56%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.09
• Shares Outstanding: 8,055,150
• 10 Day Avg. Volume: 7,315
• 30 Day Avg. Volume: 19,023
• PEG Ratio: -1.68
• Price to Book (P/B): -5.33
• Price to Sales (P/S): 2.20
• P/FCF Ratio: 19.54
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: 9.20
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $4.50 ▲(10.02% Upside)

Cryo-Cell International's overall stock score is primarily influenced by its financial performance and technical analysis. The company faces significant financial challenges, including declining revenue and high leverage, which are reflected in the low financial performance score. Technical analysis indicates bearish momentum, further impacting the score. The high dividend yield provides some support, but the negative P/E ratio highlights earnings concerns.

Positive Factors

Cash Flow Generation

The growth in free cash flow indicates improved cash generation, enhancing liquidity and providing financial flexibility for future investments.

Gross Profit Margin

A strong gross profit margin reflects efficient cost management, which can support profitability and competitive pricing strategies over time.

Operational Improvements

Improved EBIT and EBITDA margins suggest better operational efficiency, which could lead to enhanced profitability and business sustainability.

Negative Factors

Revenue Growth Decline

A significant decline in revenue growth indicates challenges in maintaining sales momentum, potentially impacting long-term market position and profitability.

Financial Instability

Negative equity and high leverage pose financial risks, limiting the company's ability to invest in growth and weather economic downturns.

Low Net Profit Margin

A low net profit margin indicates difficulty in converting revenue into profit, which can hinder long-term financial health and shareholder returns.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

How the Company Makes Money

Cryo-Cell International generates revenue through several key streams. The primary source of income comes from the fees charged for umbilical cord blood and tissue storage services. Parents pay an initial processing fee for collecting and storing the stem cells, along with annual storage fees. Additionally, CCEL may earn revenue through partnerships with healthcare providers and hospitals that refer clients for their services. The company also explores opportunities in research and development, potentially collaborating with pharmaceutical firms and academic institutions to leverage its biobanking capabilities for clinical trials and therapies, which can further enhance its revenue generation.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International faces challenges in maintaining revenue growth and profitability, with declining revenue and low net profit margins. The balance sheet shows financial instability with high leverage and negative equity, posing potential risks. However, the company demonstrates some strength in cash flow generation, which could support liquidity needs.

Income Statement

Cryo-Cell International's income statement shows a mixed performance. The gross profit margin remains strong at 77% TTM, indicating efficient cost management. However, the net profit margin is low at 1.26% TTM, reflecting challenges in translating revenue into profit. The revenue growth rate has declined significantly by 75.4% TTM, highlighting potential issues in maintaining sales momentum. EBIT and EBITDA margins have improved over the previous year, suggesting some operational improvements.

Balance Sheet

The balance sheet reveals significant financial instability, with a negative stockholders' equity of $-14.83 million TTM, indicating more liabilities than assets. The debt-to-equity ratio is negative, reflecting high leverage and potential financial risk. Return on equity is also negative, suggesting inefficiencies in generating returns from shareholders' investments. The equity ratio is not favorable, pointing to a weak capital structure.

Cash Flow

Cash flow analysis shows some positive trends, with a 6.7% growth in free cash flow TTM, indicating improved cash generation. The operating cash flow to net income ratio is 0.34 TTM, suggesting moderate cash conversion efficiency. The free cash flow to net income ratio is high at 0.95 TTM, reflecting strong cash flow relative to net income, which is a positive sign for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.75M	31.99M	31.34M	30.34M	28.88M	31.15M
Gross Profit	24.47M	24.04M	22.90M	21.54M	19.90M	21.49M
EBITDA	5.15M	1.42M	-10.42M	6.65M	5.32M	7.22M
Net Income	399.61K	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet
Total Assets	63.17M	64.68M	61.22M	64.89M	60.66M	46.20M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.50M	980.25K	1.72M	8.34M	10.45M
Total Debt	4.21M	12.93M	10.90M	11.61M	2.82M	6.24M
Total Liabilities	78.00M	77.89M	72.25M	66.41M	56.48M	48.87M
Stockholders Equity	-14.83M	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow
Free Cash Flow	6.05M	3.61M	1.28M	-8.60M	974.92K	8.02M
Operating Cash Flow	6.35M	6.01M	8.92M	8.57M	7.93M	8.47M
Investing Cash Flow	-1.80M	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
Financing Cash Flow	-4.49M	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 4.09 is below the 20-day moving average (MA) of 4.25, below the 50-day MA of 4.44, and below the 200-day MA of 5.19, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of 21.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.69M	-5.69	-8.75%	―	17.84%	-156.13%
DCGO	45 Neutral	$94.68M	―	-17.32%	―	-47.03%	-274.41%
CCEL	44 Neutral	$34.94M	-73.26	―	9.78%	-0.29%	94.56%
MODVQ	41 Neutral	$143.54K	―	―	―	-0.70%	-2.38%
CCM	38 Underperform	$22.84M	-1.01	―	―	-22.38%	56.66%
PIII	38 Underperform	$60.81M	-0.17	-257.39%	―	-2.15%	-6.72%

Cryo-Cell International Corporate Events

Cryo-Cell International Amends Credit Agreement with Susser Bank

Cryo-Cell International, Inc. announced a Fifth Amendment to its Credit Agreement with Susser Bank on October 18, 2025. This amendment includes the addition of its subsidiary, Celle Corp., as a guarantor, an extension of the maturity dates for its revolving credit and term loans, and a revision of the revolving credit commitment and applicable margins. The revolving credit commitment was reduced to $8,000,000, and the maturity dates were extended to October 18, 2027, for the revolving credit and July 29, 2032, for the term loan. These changes are expected to impact the company’s financial flexibility and operational planning.

The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Cryo-Cell Schedules 2025 Annual Stockholders Meeting

Cryo-Cell International has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025, with a record date of September 15, 2025, for determining eligible stockholders. Stockholders must submit notices for business or director nominations within ten days of the public disclosure date, September 10, 2025, as per the company’s bylaws.

The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.